Singapore-based Prestige Biopharma and Vaxine have entered into a memorandum of understanding (MoU) to collaborate on the supply of Vaxine’s COVID-19 Vaccine, Covax-19 (also known as Spikogen) and on the co-development of COVID-19/influenza combo vaccine.

Vaxine has developed a state-of-the-art recombinant protein vaccine against COVID-19 that is manufactured using insect cells and includes Vaxine’s proprietary Advax polysaccharide adjuvant. This vaccine showed efficacy against infection by the Delta variant in Phase 3 clinical trials and already is in use in the Middle East.

In December 2021, the Australian Therapeutic Goods Administration (TGA) granted a provisional determination allowing an application to be lodged for a provisional approval for this COVID-19 vaccine. Regulatory submissions are similarly underway in many other countries in parallel.

Through this MoU, Prestige and Vaxine will be building a long-term vaccine partnership, initially focused on manufacturing and commercialization of Vaxine’s COVID-19 vaccine and then as Covid-19 enters an endemic phase development of a next generation COVID-19/influenza combo vaccine as well as other vaccine projects.

The MoU will bring together Prestige’s global scale vaccine manufacturing capacity & research expertise with Vaxine’s innovative vaccine technologies including its vaccines against COVID-19, seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, dengue, malaria, allergy and cancer.